期刊文献+

聚丙交酯复合乙交酯微球经肝动脉化疗栓塞术治疗肝癌的动物实验 被引量:4

An experimental study on the therapeutic effects of Poly-Lactid-co-Glycolid(PLcG)-microspheres in the transarterial chemoembolization (TACE)
下载PDF
导出
摘要 目的 :在肝细胞癌动物模型上观察聚丙交酯复合乙交酯 (PLcG)微球经肝动脉化疗栓塞术 (TACE)治疗肝癌的疗效。方法 :在雄性ACI大鼠 ( 15例 )肝包膜下植入MorrisHepatoma 392 4A肝癌小瘤块 ( 1mm3) ,移植术后 13天时行磁共振检查。再经正中腹切开术和经胃十二指肠动脉逆行插管进行以下介入治疗 :治疗组A( 40mgPLcG + 0 .0 5mg丝裂霉素 ,4例 )、对照组B( 0 .0 5mg丝裂霉素 + 0 .0 4mg碘化油 +肝动脉结扎 ,4例 )和对照组C( 1.5ml生理盐水 ,7例 )。插管术后 13天再次行磁共振术观察肝肿瘤体积变化。结果 :在C组 ,肿瘤体积在实验期间增长 2 7.12倍 ,在B组 ,肿瘤体积增长 3.76倍 ,而在A组 ,肿瘤体积仅增长 2 .87倍。A组与C组肿瘤体积增长率在t检验时均有显著性差异 (P <0 .0 5 )。结论 :在动物实验中将PLcG微球运用于TACE可明显抑制肝肿瘤生长。 Objective:To evaluate the therapeutic effects of PLcG microspheres in the TACE in an animal model of hepatocellular carcinoma(HCC).Methods:The subcapsular implantation of a solid Morris Hepatoma 3924A (1mm 3) in the left liver was carried out at 15 male ACI rats.13 days after the implantation, the volume of tumor was measured by MRI.A laparotomy was then performed and after retrograde catheterization of the gastroduodenal artery the following protocols were carried out:(A) 40 mg PLcG +0.05 mg mitomycin (n=4);(B) 0.05 mg mitomycin+0.04 mg Lipiodol +ligation (n=4);(C) 0.9% NaCl (n=7).13 days after the injection of the materials mentioned previously, the change in the volume of tumor was determined by MRI again.Results:An obvious growth in the volume of tumor with 27.12 times in group C, with 3.76 times in group B,but a slight growth with only 2.87 times in the treated group (group A) were observed.There was a significant difference of the change in the volume of tumor between group A and group C by t test ( P <0.05).Conclusion:The growth of HCC could be inhibited using PLcG microspheres in the TACE in animal model.
出处 《放射学实践》 2001年第6期381-383,共3页 Radiologic Practice
基金 德国科教部基金资助 (0 1KS960 2 )
关键词 肝细胞癌 经肝动脉化疗栓塞术 聚丙交酯复合乙交酯 微球 治疗 Hepatocellular carcinoma Transarterial chemoembolization Poly Lactid co Glycolid Microsphere
  • 相关文献

参考文献9

  • 1[1]Pereira PL,Kopp A,Truebenbach J,et al.Primaere Lebertumoren[J].DerOnkologie,2000,6(4)∶301-310.
  • 2[2]Carlsson G,Gullberg B,Hafstroem L.Estimation of liver tumor volume using different formulas:An experimental study in rats[J].J Cancer Res Oncol,1983,105(1)∶20-23.
  • 3[3]Yang R,Liu Q,Rescorla FJ,et al.Experimental liver cancer:Improved response after hepatic artery ligation and infusion of tumor necrosis factor-alph a and interferon-gamma[J].Surgery,1995,118(4)∶768-774.
  • 4[4]Yang R,Rescorla FJ,Reilly CR,et al.A reproducible rat liver cancer model forexperimental therapy:Introducing a technique of intrahepatic tumor implantation[J].Journal of Surgery Research,1992,52(3)∶193-198.
  • 5[5]Teicher BA,Lazo JS,Sartorelli AC.Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumour cells[J].Cancer,1981,41(1)∶73-81.
  • 6[6]Kanematsu T,Maehara Y,Matsumata T,et al.Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test[J].Oncology,1991,48(1)∶34-38.
  • 7[7]Brunner KW,Nagel GA.Internistische Krebstherapie[M].Berlin:Springer,1985.17-58.
  • 8[8]Bartkowski R,Kohler H,Bastian P,et al.Novel microspheres for chemoembolization of liver metastases:Experimental studies of novikoff hepatoma in the rat[J]. Langenbecks Arch Chir,1997,114(Supp)∶319-323.
  • 9[9]Verrijk R,Smolders IJH,Bosnie N,et al.Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide[J].Cancer Research,1992,52(23)∶6653-6656.

同被引文献107

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部